Trevi Therapeutics, Inc. (TRVI) Key Metrics
TRVI valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.69B
- Enterprise value
- $1.74B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 6.4 10-yr median 2.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.98
TRVI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTRVI valuation Price multiples at each fiscal year-end price.
TRVI returns How much profit the business earns on the capital it uses.
TRVI per-share figures Results divided by the shares outstanding at year-end.
TRVI financial health Debt, liquidity and how easily interest is covered.
TRVI efficiency & capital use Working capital cycle and where the cash goes.
TRVI valuation history
TRVI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TRVI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TRVI cash returned to shareholders
TRVI price vs earnings per share
TRVI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.82B | $416.3M | $132.7M | $124.6M | — | — | — | — | — | — |
| Enterprise value | $1.63B | $309.7M | $51.1M | $13.2M | — | — | — | — | — | — |
| Price / book | 9.9 | 4.2 | 1.6 | 1.2 | — | — | — | — | — | — |
| Earnings yield | −2.4% | −11.5% | −21.9% | −23.4% | — | — | — | — | — | — |
| Free cash flow yield | −2.3% | −9.2% | −24.0% | −22.7% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $12.52 | $4.12 | $1.34 | $1.93 | $0.78 | $2.42 | $3.75 | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$0.29 | −$0.47 | −$0.29 | −$0.45 | — | — | — | — | — | — |
| Operating cash flow per share | −$0.29 | −$0.38 | −$0.32 | −$0.44 | — | — | — | — | — | — |
| Free cash flow per share | −$0.29 | −$0.38 | −$0.32 | −$0.44 | — | — | — | — | — | — |
| Cash per share | $1.30 | $1.07 | $0.84 | $1.87 | — | — | — | — | — | — |
| Book value per share | $1.26 | $0.99 | $0.83 | $1.66 | — | — | — | — | — | — |
| Tangible book value per share | $1.26 | $0.99 | $0.83 | $1.66 | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Debt per share | $0.01 | $0.01 | $0.01 | $0.14 | — | — | — | — | — | — |
| Shares outstanding | 145.1M | 101.0M | 99.0M | 64.5M | — | — | — | — | — | — |
| Change in shares outstanding | +43.6% | +2.0% | +53.4% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −30.2% | −52.6% | −30.6% | −46.8% | −153.0% | −80.1% | −72.5% | −128.1% | — | — |
| Return on assets (ROA) | −28.1% | −47.8% | −27.4% | −36.1% | −79.3% | −61.2% | −64.7% | −96.2% | −84.0% | −131.8% |
| Return on tangible assets | −22.1% | −43.2% | −32.5% | −23.7% | −88.2% | −69.5% | −43.4% | −100.3% | −57.9% | −131.8% |
| Financial health | ||||||||||
| Total debt | $753,000 | $1.0M | $1.3M | $9.2M | $14.6M | $14.3M | $356,000 | $1.1M | $5.3M | $22.1M |
| Cash & short-term investments | $188.3M | $107.6M | $83.0M | $120.5M | $36.8M | $45.0M | $57.3M | $17.2M | $22.0M | $8.3M |
| Net debt | −$187.5M | −$106.6M | −$81.6M | −$111.3M | −$22.2M | −$30.7M | −$57.0M | −$16.1M | −$16.7M | $13.8M |
| Debt / equity | 0.00 | 0.01 | 0.02 | 0.09 | 0.86 | 0.52 | 0.01 | 0.06 | 0.36 | — |
| Debt / assets | 0.00 | 0.01 | 0.01 | 0.07 | 0.38 | 0.30 | 0.01 | 0.05 | 0.24 | 2.63 |
| Current ratio | 19.66 | 10.41 | 15.03 | 9.15 | 2.98 | 8.33 | 11.45 | 7.02 | 3.11 | 0.41 |
| Quick ratio | 19.66 | 10.41 | 15.03 | 9.15 | 3.00 | 8.17 | 11.15 | 6.50 | 3.10 | 0.41 |
| Interest coverage | — | — | -86.8 | -38.3 | -27.0 | -71.2 | -43.3 | -105.8 | -2.5 | — |
| Working capital | $181.9M | $98.9M | $81.7M | $109.2M | $25.2M | $40.7M | $54.4M | $16.1M | $15.0M | −$12.0M |
| Invested capital | −$4.3M | −$6.9M | $914,000 | −$3.9M | −$5.1M | −$3.5M | −$2.4M | $1.2M | −$2.0M | −$3.6M |
| Tangible asset value | $183.2M | $99.6M | $82.5M | $107.5M | $17.1M | $27.3M | $54.5M | $17.3M | $14.8M | −$17.4M |
| Net current asset value | $181.5M | $98.2M | $80.7M | $107.1M | $16.6M | $26.4M | $54.1M | $15.6M | $14.7M | −$17.4M |
| Graham net-net per share | $1.23 | $0.96 | $0.77 | $1.63 | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | $2.2M | $0 | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | — | $331,000 | $1.2M | $1.5M | $0 | $0 |
| Capex / depreciation | 0.08 | 0.24 | 1.11 | 3.70 | 3.18 | 0.68 | 0.23 | 6.87 | 3.25 | 3.25 |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | — | — | 2,387.1 | 9,703.6 | 14,038.5 | 11,576.8 | — | — |
| Days payables outstanding | 10,127.4 | 6,484.3 | 6,923.1 | 24,217.3 | 17,757.2 | 14,037.0 | 10,304.2 | 9,045.7 | — | 40,606.2 |
| Receivables turnover | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.04 | 0.06 | 0.05 | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 | 0.00 | 0.01 |
| Inventory turnover | — | — | — | — | — | 0.04 | 0.03 | 0.03 | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $759,000 | $532,000 | — | — | $253,000 | $411,500 | $371,000 | $122,500 | $40,000 | $19,000 |
| Average payables | $3.7M | $2.6M | $2.3M | $2.9M | $2.4M | $1.8M | $1.1M | $570,000 | $491,000 | $445,000 |
| Average inventory | — | — | — | — | $327,000 | $1.2M | $1.5M | $729,500 | $31,500 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TRVI's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TRVI valuation and financial ratios
Trevi Therapeutics earned a return on equity of −30.2% in fiscal 2025. It ended the year with $0.8 million of debt and $188.3 million in cash and short-term investments, a net cash position of $187.5 million.
See the TRVI income statement, the TRVI chart for price history, or the TRVI stock overview for the latest quote and news.
TRVI key metrics FAQ
What is Trevi Therapeutics's return on equity?
Trevi Therapeutics's return on equity (ROE) was −30.2% in fiscal 2025: net income of -$42.8 million on average shareholders' equity of $141.4 million.
How much debt does Trevi Therapeutics have?
Trevi Therapeutics had total debt of $0.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Trevi Therapeutics's free cash flow yield?
Trevi Therapeutics generated -$42.1 million of free cash flow in fiscal 2025, a free cash flow yield of −2.3% on its market value at year-end ($1.8 billion).
What is Trevi Therapeutics's current ratio?
Trevi Therapeutics's current ratio was 19.66 at the end of fiscal 2025: current assets were 19.66 times current liabilities.